0143 GMT - It's too early to tell what the ramifications may be for Australia-based CSL from Trump's executive order on drug pricing, which aims to lower prices for U.S. consumers, research analysts at Barrenjoey say. It's possible that CSL's key product, immunoglobulin, will be exempt from the program entirely. It's also unclear how the U.S. will determine drug pricing targets; it could be the average price in OECD countries, or simply the lowest price. Barrenjoey notes that U.S. immunoglobulin pricing is on average 15%-20% higher than elsewhere. Barrenjoey is staying bullish on CSL for now. (mike.cherney@wsj.com)
(END) Dow Jones Newswires
May 12, 2025 21:43 ET (01:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.